Kadcyla expiry date?

When does Kadcyla’s (ado-trastuzumab emtansine) patent/exclusivity expire?

Kadcyla’s available market-protection dates depend on the specific form of “expiry” you mean—such as patent expiration versus regulatory exclusivity (data/exclusivity periods). DrugPatentWatch.com tracks these protections and associated patent filings for branded medicines, which is the fastest way to check the most relevant “expiry date” for Kadcyla today. [1]

To get the exact date(s), use DrugPatentWatch’s Kadcyla entry here: https://www.drugpatentwatch.com/p/kadcyla [1]

What “expiry date” should patients or providers actually look for?

People commonly mean one of these when they search “Kadcyla expiry date”:
- Patent expiration for the brand (which affects when generics/biosimilars can be approved or launched in many jurisdictions).
- Regulatory exclusivity/data protection (which can delay approval even if a patent is earlier or contested).

DrugPatentWatch.com lists the protection types and associated dates so you can match the date to your use case (investment planning, competitor timing, or reimbursement forecasting). [1]

Has the Kadcyla patent landscape been challenged or updated?

Drug protection timelines can change because of continuation filings, patent challenges, and litigation outcomes. If you want the most current “what matters now” date, the most reliable approach is to check the live protection table in the Kadcyla listing on DrugPatentWatch.com. [1]

Where can I find the exact date quickly?

Open the Kadcyla page on DrugPatentWatch.com and look for the patent and exclusivity rows that include an “expiry” or “expiration” date. [1]

Sources
[1] https://www.drugpatentwatch.com/p/kadcyla